Ozempic Tablets Are Here: What Changed When Rybelsus Became Ozempic, Dose by Dose

Written by Dr. Sheri Tomas. Updated October 27, 2026.

Rybelsus and Ozempic are the same drug, semaglutide, and since 2026 they are also the same brand: on February 4, 2026 the FDA approved Novo Nordisk's request to rename its oral semaglutide tablet from Rybelsus to Ozempic, and the renamed tablets reached US pharmacies on May 4, 2026. What confuses people is that the numbers on the box changed at the same time. Rybelsus came in 3, 7 and 14 mg; Ozempic tablets come in 1.5, 4 and 9 mg. That is not a weaker pill. It is a reformulated tablet that delivers the same amount of drug into the blood from a smaller dose, so a person on Rybelsus 7 mg moves to Ozempic 4 mg and a person on 14 mg moves to 9 mg, with the same effect and the same side effects.

This guide explains what changed and what did not, how the three strengths map onto the old ones, how the tablet compares with the Ozempic injection and with the separate Wegovy pill for weight loss, what the new cardiovascular indication means, what the tablets cost, and what to do if you still have Rybelsus in the cupboard.

Two reasons, one commercial and one practical. Commercially, Ozempic is one of the best-known drug names in the world and Rybelsus never was; putting the tablet under the Ozempic name tells patients and prescribers at a glance that it is the same drug. Practically, Novo had already developed an improved tablet formulation that absorbs more efficiently, which the FDA had cleared on the basis of bioequivalence and clinical data showing matching efficacy and safety. Launching the new formulation under the new name let the company reset the dose numbers without two products called Rybelsus with different milligram strengths circulating at once. The sequence was: FDA approval of the name change and new strengths on February 4, 2026; US availability from May 4, 2026; and a phased withdrawal of Rybelsus from US distribution over the following months, with insurers telling members by late summer that Rybelsus prescriptions would need to be rewritten. How semaglutide got from a weekly injection to a daily tablet at all is covered in what is Ozempic.

Oral semaglutide is a difficult drug to make into a pill, because peptides are digested in the stomach. Rybelsus solved this by combining semaglutide with an absorption enhancer called SNAC, which briefly raises the pH around the tablet so the drug can cross the stomach lining. Only about 1% of the dose reached the blood, which is why Rybelsus needed 14 mg to match an Ozempic injection of around 0.5 to 1 mg. The 2026 formulation improves that absorption, so a 9 mg tablet produces the same blood levels as the old 14 mg, and 4 mg matches 7 mg. The strengths were chosen to be bioequivalent, meaning the same amount of drug in the body, which is why the trials found the same HbA1c reduction and the same side-effect profile. It also means the tablets are not interchangeable milligram for milligram with the old product, and a pharmacist cannot simply substitute a 7 mg Rybelsus tablet for a 4 mg Ozempic tablet without a new prescription.

There are now three semaglutide products a person might be handed, and two of them are called Ozempic. The injection is the weekly pen, approved for type 2 diabetes, cardiovascular risk reduction in people with established heart disease, and slowing kidney disease in people with diabetes and chronic kidney disease. The tablets are the daily pill for type 2 diabetes with a cardiovascular indication of their own. The Wegovy pill is the daily 25 mg tablet approved in December 2025 for chronic weight management, using the same improved formulation at a much higher dose. They share the warnings and the gut side effects, and they differ in what they are for, how much drug they deliver and what they cost.

The full comparison between branded Ozempic and other semaglutide, including compounded versions, is in Ozempic vs semaglutide. The weight-loss question, and why Ozempic in either form is not the product for it, is covered in is Ozempic approved for weight loss.

Rybelsus was approved for blood sugar only. The 2026 label for Ozempic tablets adds reduction of major adverse cardiovascular events, heart attack, stroke and cardiovascular death, in adults with type 2 diabetes at high cardiovascular risk, covering both people who have already had an event and people who have risk factors but no event yet. The evidence comes from the SOUL trial, a 9,650-person outcomes study of oral semaglutide published in 2025, which found a 14% relative reduction in major cardiovascular events over about four years. That is a smaller effect than the 26% seen with the injection in SUSTAIN-6, but in a broader and lower-risk population, and it moves the tablet from a glucose drug to a drug a cardiologist might recommend. For people who will not inject, it closes most of the gap with the pen. The injection still holds the kidney indication on its own.

The rules are the same as for Rybelsus and they matter more than for almost any other pill, because the absorption enhancer only works in an empty, nearly dry stomach. Take the tablet when you wake, before anything else. Swallow it whole with no more than 4 ounces of plain water; do not split, crush or chew it. Wait at least 30 minutes before eating, drinking anything else or taking other medicines, including thyroid tablets and vitamins. Taking it with food or a full glass of water does not make it dangerous; it makes it not work, because far less drug is absorbed. If you miss a day, skip it and take the next day's tablet as usual; do not double up. Start at 1.5 mg for 30 days, then 4 mg; increase to 9 mg after at least 30 days if more glucose lowering is needed. Expect the usual semaglutide gut effects in the first weeks of each step; our guide to Ozempic diarrhea applies equally to the tablet.

No. The tablets carry the same label warnings as the injection: the boxed warning about thyroid C-cell tumours in rodents, pancreatitis, gallbladder disease, dehydration-related kidney injury, low blood sugar when combined with insulin or sulfonylureas, diabetic retinopathy complications, and the precaution about delayed stomach emptying before anaesthesia. The common effects are nausea, diarrhea, constipation, abdominal pain and reduced appetite, and in the oral trials they were somewhat less frequent at 9 mg than with the 1 mg injection, because the blood levels are lower. The full list, with trial frequencies, is on our Ozempic side effects page.

The tablet suits people with type 2 diabetes who will not inject, who travel without a fridge, or who prefer a daily routine to a weekly one. It costs less at self-pay prices and now carries a cardiovascular indication. The injection suits people who need the stronger glucose and weight effect of the 1 mg and 2 mg doses, people with chronic kidney disease, where only the injection has the indication, and people who struggle with the fasting rule, which is the single most common reason the tablet underperforms in practice. Neither is for weight loss alone. People with diabetes choosing between them should read Ozempic for diabetes; the mechanism they share is in how Ozempic works.

The list price is the same as the injection, about $1,027 a month, and Novo has announced that list prices across its semaglutide products fall to $675 in January 2027. Almost nobody pays list. The NovoCare self-pay program charges $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg, available without insurance. For commercially insured patients the savings card brings the copay to as little as $25 for up to a three-month fill. Insurance coverage follows the diabetes diagnosis: plans that covered Rybelsus cover Ozempic tablets, and plans are moving members over as the old product leaves the market. Medicare Part D covers the tablets for diabetes as it did Rybelsus. The pricing landscape, including GoodRx and what changes in 2027, is in how much Ozempic costs per month and does insurance cover Ozempic.

Rybelsus and Ozempic have always been the same drug. Since May 2026 they are the same brand too: Ozempic tablets in 1.5, 4 and 9 mg replace Rybelsus 3, 7 and 14 mg, with better absorption, identical effect, a new cardiovascular indication and lower self-pay prices. The conversion is simple, 7 becomes 4 and 14 becomes 9, and the rules for taking it have not changed. What has not changed either is the purpose: Ozempic tablets are for type 2 diabetes, and the semaglutide pill for weight loss is called Wegovy. We track label changes and launches in Ozempic news.

Product details are current as of October 2026 and may change; check the current label and your pharmacy.